TAK 187

Drug Profile

TAK 187

Latest Information Update: 16 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antifungals
  • Mechanism of Action 14-alpha demethylase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 16 Oct 2000 Discontinued-Preclinical for Mycoses in Japan (Unknown route)
  • 12 Jun 2000 No-Development-Reported for Mycoses in Japan (Unknown route)
  • 17 Dec 1998 A preclinical study has been added to the Mycoses antimicrobial activity and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top